Supplementary Materials

Supplementary Material for:

Eradication of spontaneous malignancy by local immunotherapy

Idit Sagiv-Barfi, Debra K. Czerwinski, Shoshana Levy, Israt S. Alam, Aaron T. Mayer, Sanjiv S. Gambhir, Ronald Levy*

*Corresponding author. Email: levy{at}stanford.edu

Published 31 January 2018, Sci. Transl. Med. 10, eaan4488 (2018)
DOI: 10.1126/scitranslmed.aan4488

This PDF file includes:

  • Fig. S1. In situ vaccination with a TLR9 ligand induces the local expression of OX40 but not that of PD1 or CTLA4.
  • Fig. S2. CpG induces the expression of OX40 on CD4 T cells.
  • Fig. S3. Cytokines are playing a role in the CpG T cell cross-talk.
  • Fig. S4. Intracellular IFN-γ production of CD4+ cells.
  • Fig. S5. Frequency of T cell subsets.
  • Fig. S6. Tumor recurrence is sensitive to treatment with anti-OX40 and CpG.
  • Fig. S7. Resiquimod (R848) in combination with anti-OX40 and anti-PD1/PDL1 in combination with CpG.
  • Fig. S8. In situ vaccination with CpG and anti-OX40 is effective against breast carcinoma, colon cancer, and melanoma.
  • Fig. S9. Dose de-escalation of CpG and αOX40 antibody.
  • Fig. S10. Systemic administration of anti-αOX40 antibody.
  • Fig. S11. Long-term memory in cured mice.
  • Fig. S12. Confirmation of Treg depletion from the tumor.
  • Fig. S13. Anti-OX40 antibody stimulates Teffs and inhibits function of Tregs.
  • Fig. S14. Requirement for Fc competency of the anti-OX40 antibody.
  • Fig. S15. Neither Tregs nor Teffs are depleted by anti-OX40 antibody.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Primary data (provided as an Excel file)..